Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A.
Musa F, et al. Among authors: speyer jl.
Gynecol Oncol. 2017 Feb;144(2):279-284. doi: 10.1016/j.ygyno.2016.11.043. Epub 2016 Dec 5.
Gynecol Oncol. 2017.
PMID: 27931751
Clinical Trial.